

Advance Contract Award Notice (ACAN)
Solicitation Number: 210031

TITLE: *IQVIA PharmaQuery – International Online Guide for Pricing and Reimbursement*

1. The purpose and explanation of an ACAN

An ACAN is a public notice indicating to the supplier community that a department or agency intends to award a contract for goods, services or construction to a pre-identified supplier, thereby allowing other suppliers to signal their interest in bidding, by submitting a statement of capabilities. If no supplier submits a statement of capabilities that meets the requirements set out in the ACAN, on or before the closing date stated in the ACAN, the contracting officer may then proceed with the award to the pre-identified supplier.

2. Rights of suppliers

Suppliers who consider themselves fully qualified and available to provide the services or goods described in this ACAN may submit a Statement of Capabilities demonstrating how they meet the advertised requirement. This Statement of Capabilities must be provided **via e-mail only** to the contact person identified in Section 12 of the Notice, on or before the closing date and time of the Notice. If there is a reasonable level of evidence regarding capability the requirement will be opened to electronic or traditional bidding processes.

3. Proposed Contractor

IQVIA Ltd.
210 Pentonville Road,
London N1 9JY, England

4. Definition of Requirements or Expected Results

The PMPRB gathers intelligence on international pricing and reimbursement regimes/policies and trends to carry out its price review process, develop strategic advice and report on national and international trends. To perform these functions, the PMPRB needs to invest considerable resources both internally and externally to gathering and analyzing the best available information on global pricing and reimbursement of pharmaceuticals.

The contractor will provide:

- Detailed coverage of the changing pricing & reimbursement (P&R) landscape in 31 key world markets:

Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Russia, South Korea, Spain, Sweden, Switzerland, Turkey, UK and USA.

- Weekly pricing & reimbursement news feed, archived back to over 16,000 fully

searchable news stories dating from 1998

- Detailed analysis of pricing & reimbursement rules and regulations and healthcare systems
- Benchmark reports with comparative facts and figures on key pricing & reimbursement indicators
- Access to PP&R monthly magazine.

Pricing & Reimbursement Systems: A comprehensive database of healthcare systems in key world markets, including detailed pricing and reimbursement regulations, updated quarterly on a rolling basis.

Chapters and Headings are as follows:

Healthcare Systems (Facts, Figures, Provision & Funding)

Pricing (Prescription Drugs, generic Drugs, Hospital Drugs, OTC Drugs)

Reimbursement (Admission to Reimbursements, Reimbursement Categories, Reimbursement Prices, Hospital Reimbursement Changes in reimbursement Status, Changes in Reimbursement Prices)

Pharmacoeconomics (Pharmacoeconomic Requirements)

Price Build Up (Wholesalers, Retail Pharmacies, Dispensing Doctors, Sales Tax)

Cost Containment (Industry Payback, Promotional Costs, Patient Co-payments, Prescribing Controls, Generics, Rx-to OTC Switches, Parallel Trade)

Future Developments (Outlook)

Additional resources (Names & Addresses, Terminology, Links and more)

Pricing & Reimbursement News: Weekly news service delivered direct to your desktop, hyperlinked throughout the site to related News stories. Archive of fully searchable News stories dating back to 1998.

IQVIA Pharma Pricing and Reimbursement Magazine: A monthly information resource designed to guide key decision-makers in industry, government and third-party organisations through the maze of pricing and reimbursement.

Pharmaceutical Pricing & Reimbursement Concise Guide: The definitive guide to pricing & reimbursement, market access, cost containment, trade margins and healthcare systems in major markets worldwide

PMPRB upgrade to PP&R + Executive Summaries.

- Executive summaries with policy impact analysis offer quick, digestible and comparable analysis of the Pricing & Reimbursement environment
- Supported by visual policy impact analysis for immediate understanding of the key P&R policies that are impacting drug maker revenues, covering the leading pharmaceutical markets.

5. Minimum requirements

Any interested supplier must demonstrate by way of a Statement of Capabilities that it meets the following minimum requirements:

- An ability to provide comprehensively sources and timely analysis of pricing & reimbursement (P&R) regime and developments in key world markets: (Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, UK and USA. Including news updates by a team of international pricing & reimbursement experts, fully sourced and linked to primary and secondary information sources, and personal contacts and support.
- Thought Leadership articles/White Papers, providing unique perspectives and insights from IQVIA LTD. into P&R issues.
- Novel and consistent methodology to aid international comparisons; enhanced by the availability of tabular reports to assist in benchmarking activities and Advanced search tools and hyperlinks to enable rigorous database interrogation.

6. Reason for non-competitive award

In accordance with the Government Contracts Regulations (GCR) of the *Financial Administration Act*, the following request falls under exception 6(d) of the GCR, which stipulates that only one person or contractor is capable of performing the contract.

IQVIA LTD. is a recognized industry leader that is often referenced by stakeholders from both the pharmaceutical industry as well as payers. IQVIA LTD. has a proven track record with the organization of excellence, timeliness and precision. The company has demonstrated expertise in both the collection of market data as well as in interpretation of these data. IQVIA LTD. is the only company known to the organization to be able to meet consistently the required information in the complete, objective and non-biased fashion, with supporting documentation and access to international and external experts and source documentation and insights. Increasingly the PMPRB has been relying on pricing and utilization data from IQVIA LTD. for both regulatory as well as reporting purposes and has gained both confidence as well as experience with IQVIA LTD. as a source of information. IQVIA LTD. is the supplier of various other domestic and international intelligence and is in a unique position to combine market insights with substantiating analytics from a network of data suppliers and international experts. P&R information that compliments the data and price information housed at the PMPRB will provide even greater interpretive power to position the PMPRB for future priorities. No other data/market intelligence supplier can provide the type of information that would be sufficient to our needs. The subscription will add qualitative and quantitative information to existing databases with the same specifications and would allow for consistent interpretation of finding.

7. Applicability of the trade agreement(s) to the procurement

This procurement is subject to the following trade agreements:

Canadian Free Trade Agreement (CFTA)

Canada-Chile Free Trade Agreement

Canada-Colombia Free Trade Agreement

Canada-Honduras Free Trade Agreement

Canada-Korea Free Trade Agreement (CKFTA)

Canada-Panama Free Trade Agreement

Canada-Peru Free Trade Agreement (CPFTA)

8. Ownership of Intellectual Property

Ownership of any Foreground Intellectual Property arising out of the proposed contract will vest with the Contractor.

9. Period of the proposed contract

The proposed contract is for a period of one (1) year after the award of the contract with an irrevocable option on the part of Canada to extend the period of any resulting contract by up to four (4) additional one (1) year periods.

10. Estimated value of the proposed contract

The total estimated value of the proposed contract should not exceed \$192,606.63 USD including all option periods, travel and living expenses (if applicable), and all applicable taxes.

11. Closing date and time

The closing date and time for accepting Statements of Capabilities is:
March 31, 2021 at 14:00 Eastern Daylight Time (EDT)

12. Contact Person

All inquiries with regard to this Notice must be addressed by e-mail to:

Name: Nadia Laneve

E-Mail: nadia.laneve@pmprb-cepmb.gc.ca